Total Payments
$80,218
2024 Payments
$3,662
Companies
29
Transactions
211
Medicare Patients
2,695
Medicare Billing
$321,861
Payment Breakdown by Category
Other$59,315 (73.9%)
Travel$8,144 (10.2%)
Food & Beverage$6,941 (8.7%)
Consulting$5,710 (7.1%)
Education$108.49 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,115 | 21 | 56.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $14,200 | 5 | 17.7% |
| Travel and Lodging | $8,144 | 19 | 10.2% |
| Food and Beverage | $6,941 | 162 | 8.7% |
| Consulting Fee | $5,710 | 2 | 7.1% |
| Education | $108.49 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $48,194 | 101 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $14,364 | 16 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,971 | 5 | $0 (2019) |
| Shionogi Inc | $5,664 | 9 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,266 | 12 | $0 (2023) |
| Gilead Sciences, Inc. | $1,736 | 16 | $0 (2020) |
| Lilly USA, LLC | $272.67 | 3 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $255.45 | 6 | $0 (2023) |
| Madrigal Pharmaceuticals | $236.10 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $227.03 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,662 | 32 | ABBVIE INC. ($2,668) |
| 2023 | $4,498 | 16 | ABBVIE INC. ($4,382) |
| 2022 | $12,899 | 31 | ABBVIE INC. ($12,749) |
| 2021 | $1,771 | 20 | AbbVie Inc. ($1,410) |
| 2020 | $2,827 | 14 | AbbVie Inc. ($2,508) |
| 2019 | $17,794 | 31 | AbbVie, Inc. ($10,329) |
| 2018 | $9,926 | 13 | AbbVie, Inc. ($7,663) |
| 2017 | $26,840 | 54 | Valeant Pharmaceuticals North America LLC ($14,364) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: LIVER DISEASE | ||||||
| 12/09/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $29.92 | General |
| Category: VIROLOGY | ||||||
| 11/26/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | Cash or cash equivalent | $121.82 | General |
| Category: Immunology | ||||||
| 11/08/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $10.93 | General |
| Category: LIVER DISEASE | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: Immunology | ||||||
| 11/01/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $135.77 | General |
| Category: LIVER DISEASE | ||||||
| 10/21/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: VIROLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: VIROLOGY | ||||||
| 10/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $10.42 | General |
| Category: LIVER DISEASE | ||||||
| 10/08/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: LIVER DISEASE | ||||||
| 09/26/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $121.86 | General |
| Category: VIROLOGY | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $124.40 | General |
| 08/29/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: GI | ||||||
| 08/22/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Hematology | ||||||
| 08/14/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: VIROLOGY | ||||||
| 08/01/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Immunology | ||||||
| 07/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/23/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.51 | General |
| Category: Neuroscience | ||||||
| 07/02/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: VIROLOGY | ||||||
| 06/19/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $29.74 | General |
| Category: Immunology | ||||||
| 06/06/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $102.63 | General |
| Category: Neuroscience | ||||||
| 06/03/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: VIROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 567 | 620 | $300,426 | $62,434 |
| 2022 | 11 | 621 | 731 | $306,829 | $72,032 |
| 2021 | 13 | 724 | 927 | $353,085 | $89,482 |
| 2020 | 16 | 783 | 1,137 | $399,499 | $97,912 |
Total Patients
2,695
Total Services
3,415
Medicare Billing
$321,861
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 90 | 97 | $42,777 | $13,017 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $30,855 | $10,303 | 33.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 105 | 106 | $83,952 | $8,150 | 9.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 61 | 61 | $66,002 | $7,898 | 12.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 96 | 109 | $17,331 | $6,796 | 39.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 58 | 89 | $14,062 | $5,573 | 39.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 24 | 24 | $29,232 | $5,201 | 17.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 18 | 19 | $9,101 | $2,976 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 13 | $3,068 | $1,341 | 43.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $4,046 | $1,179 | 29.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 111 | 120 | $52,920 | $18,077 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 122 | 161 | $25,599 | $9,966 | 38.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 80 | 80 | $29,040 | $9,705 | 33.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 57 | 57 | $61,674 | $7,903 | 12.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 82 | 143 | $22,594 | $7,802 | 34.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 87 | 88 | $69,696 | $6,192 | 8.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 17 | 17 | $20,706 | $3,554 | 17.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 17 | 17 | $8,143 | $3,015 | 37.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 17 | 17 | $8,143 | $2,970 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 12 | $3,792 | $1,435 | 37.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 19 | 19 | $4,522 | $1,412 | 31.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 136 | 146 | $64,386 | $22,704 | 35.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 102 | 233 | $36,814 | $13,519 | 36.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 118 | 166 | $26,394 | $11,225 | 42.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 104 | 106 | $83,952 | $8,679 | 10.3% |
About Dr. Rashid Khan, MD
Dr. Rashid Khan, MD is a Hepatology healthcare provider based in Baytown, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437211786.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rashid Khan, MD has received a total of $80,218 in payments from pharmaceutical and medical device companies, with $3,662 received in 2024. These payments were reported across 211 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($45,115).
As a Medicare-enrolled provider, Khan has provided services to 2,695 Medicare beneficiaries, totaling 3,415 services with total Medicare billing of $321,861. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Gastroenterology, Internal Medicine
- Location Baytown, TX
- Active Since 12/14/2006
- Last Updated 10/29/2025
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1437211786
Products in Payments
- Mavyret (Drug) $24,175
- MAVYRET (Drug) $23,479
- XIFAXAN (Drug) $11,916
- Stivarga (Drug) $5,971
- RELISTOR (Drug) $4,714
- OMVOH (Drug) $272.67
- OCALIVA (Drug) $255.45
- RESMETIROM (Drug) $236.10
- DUPIXENT (Biological) $197.96
- uTASWako AFP-L3 (Device) $167.41
- INJECTAFER (Drug) $160.63
- RINVOQ (Biological) $155.70
- ZEPOSIA (Drug) $140.15
- Epclusa (Drug) $124.24
- Viekira (Drug) $118.00
- ENTYVIO (Biological) $87.22
- Mulpleta (Drug) $61.99
- LINZESS (Drug) $51.74
- HUMIRA (Biological) $46.74
- STELARA (Biological) $44.40
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.